X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (3606) 3606
Book Review (309) 309
Publication (88) 88
Newsletter (32) 32
Magazine Article (16) 16
Newspaper Article (16) 16
Conference Proceeding (4) 4
Book Chapter (2) 2
Paper (2) 2
Dissertation (1) 1
Trade Publication Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (3038) 3038
humans (2711) 2711
male (2138) 2138
hypertension - drug therapy (1891) 1891
female (1755) 1755
middle aged (1639) 1639
hydrochlorothiazide (1599) 1599
hydrochlorothiazide - administration & dosage (1443) 1443
hydrochlorothiazide - therapeutic use (1232) 1232
adult (1181) 1181
aged (1149) 1149
drug therapy, combination (1129) 1129
blood pressure - drug effects (1102) 1102
hypertension (1069) 1069
antihypertensive agents - administration & dosage (718) 718
diuretics (704) 704
pharmacology & pharmacy (701) 701
antihypertensive agents - therapeutic use (694) 694
double-blind method (606) 606
hydrochlorothiazide - adverse effects (591) 591
hypertension - physiopathology (580) 580
hydrochlorothiazide - pharmacology (528) 528
drug combinations (522) 522
treatment outcome (487) 487
abridged index medicus (482) 482
animals (456) 456
peripheral vascular disease (428) 428
antihypertensive agents - adverse effects (402) 402
blood pressure (369) 369
time factors (362) 362
drug therapy (347) 347
blood-pressure (346) 346
clinical trials as topic (331) 331
dose-response relationship, drug (325) 325
diuretics - therapeutic use (310) 310
rats (307) 307
diuretics - administration & dosage (288) 288
dosage and administration (281) 281
medicine, general & internal (262) 262
amlodipine (248) 248
tetrazoles - administration & dosage (248) 248
valsartan (246) 246
adolescent (226) 226
cardiac & cardiovascular systems (226) 226
tetrazoles - therapeutic use (218) 218
therapy (215) 215
risk factors (213) 213
antihypertensive agents - pharmacology (210) 210
hypertension - complications (205) 205
heart rate - drug effects (202) 202
potassium - blood (198) 198
research (198) 198
hypertension - blood (197) 197
prospective studies (195) 195
administration, oral (194) 194
aged, 80 and over (193) 193
double-blind (191) 191
angiotensin-converting enzyme inhibitors - administration & dosage (181) 181
combination therapy (175) 175
efficacy (174) 174
losartan (169) 169
sodium chloride symporter inhibitors - administration & dosage (167) 167
amlodipine - administration & dosage (162) 162
random allocation (161) 161
angiotensin-converting enzyme inhibitors - therapeutic use (160) 160
antihypertensive drugs (159) 159
diuretics - pharmacology (159) 159
medicine & public health (157) 157
pharmacokinetics (157) 157
tetrazoles - adverse effects (156) 156
management (153) 153
prevention (150) 150
sodium chloride symporter inhibitors - therapeutic use (149) 149
drug administration schedule (146) 146
analysis (144) 144
follow-up studies (144) 144
internal medicine (143) 143
renin - blood (142) 142
amlodipine - therapeutic use (141) 141
health aspects (141) 141
valine - analogs & derivatives (141) 141
tablets (139) 139
diuretics - adverse effects (138) 138
drugs (135) 135
hydrochlorothiazide - pharmacokinetics (135) 135
combination (134) 134
risk (133) 133
angiotensin ii type 1 receptor blockers - therapeutic use (132) 132
drug interactions (130) 130
urology & nephrology (129) 129
care and treatment (128) 128
mortality (125) 125
chemistry, analytical (123) 123
pharmacology/toxicology (123) 123
amiloride - administration & dosage (119) 119
angiotensin ii type 1 receptor blockers - administration & dosage (118) 118
losartan - administration & dosage (118) 118
enalapril (115) 115
captopril - administration & dosage (114) 114
cross-over studies (114) 114
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (3275) 3275
German (115) 115
Russian (76) 76
Italian (48) 48
French (40) 40
Japanese (22) 22
Spanish (22) 22
Polish (14) 14
Chinese (13) 13
Czech (11) 11
Portuguese (7) 7
Danish (3) 3
Hebrew (3) 3
Hungarian (3) 3
Norwegian (3) 3
Slovak (3) 3
Swedish (3) 3
Croatian (2) 2
Lithuanian (2) 2
Romanian (2) 2
Dutch (1) 1
Korean (1) 1
Turkish (1) 1
Ukrainian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


European Journal of Preventive Cardiology, ISSN 2047-4873, 7/2015, Volume 22, Issue 7, pp. 920 - 930
Background Most individuals at high cardiovascular disease (CVD) risk worldwide do not receive any or optimal preventive drugs. We aimed to determine whether... 
blood pressure | Cardiovascular disease | cholesterol | polypill | adherence | prevention | NON-INDIGENOUS PEOPLE | DRUG-THERAPY | DESIGN | CARDIAC & CARDIOVASCULAR SYSTEMS | MANAGEMENT | RATIONALE | MEDICATION NONADHERENCE | IMPACT | GAP | Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage | Hyperlipidemias - blood | Prospective Studies | Tablets | Cardiovascular Diseases - prevention & control | Cholesterol - blood | Humans | Middle Aged | Antihypertensive Agents - administration & dosage | Hypertension - drug therapy | Male | Aspirin - administration & dosage | Hyperlipidemias - diagnosis | Polypharmacy | Time Factors | Platelet Aggregation Inhibitors - administration & dosage | General Practice | Sodium Chloride Symporter Inhibitors - administration & dosage | Cardiovascular Diseases - blood | Female | Adrenergic beta-1 Receptor Antagonists - administration & dosage | Blood Pressure - drug effects | Atenolol - administration & dosage | Hypertension - diagnosis | Hyperlipidemias - complications | Cardiovascular Diseases - diagnosis | Lisinopril - administration & dosage | Cardiovascular Diseases - etiology | Cardiovascular Diseases - physiopathology | Administration, Oral | Simvastatin - administration & dosage | Hyperlipidemias - drug therapy | Risk Factors | Drugs, Generic - administration & dosage | Treatment Outcome | Hydrochlorothiazide - administration & dosage | Biomarkers - blood | Angiotensin-Converting Enzyme Inhibitors - administration & dosage | Hypertension - physiopathology | Primary Prevention - methods | Hypertension - complications | Aged | Australia | Drug Combinations | Index Medicus
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 05/2016, Volume 374, Issue 21, pp. 2032 - 2043
In a 2-by-2 factorial trial, 12,705 persons at intermediate risk were assigned to candesartan plus hydrochlorothiazide or placebo and to rosuvastatin or... 
STROKE | MORTALITY | TRIALS | MEDICINE, GENERAL & INTERNAL | RISK-FACTORS | COUNTRIES | THERAPY | MYOCARDIAL-INFARCTION | STRATEGY | PREVENTION | INTERHEART | Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage | Double-Blind Method | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Risk Factors | Rosuvastatin Calcium - adverse effects | Antihypertensive Agents - administration & dosage | Hypertension - drug therapy | Male | Hydrochlorothiazide - administration & dosage | Rosuvastatin Calcium - administration & dosage | Antihypertensive Agents - adverse effects | Medication Adherence | Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects | Benzimidazoles - administration & dosage | Tetrazoles - administration & dosage | Cardiovascular Diseases - epidemiology | Cholesterol, LDL - blood | Female | Aged | Drug Therapy, Combination | Care and treatment | Usage | Clinical trials | Rosuvastatin | Dosage and administration | Cardiovascular diseases | Risk factors | Myocardial infarction | Cerebral infarction | Lipoproteins (low density) | Stroke | Cardiovascular disease | Lipids | Hydrochlorothiazide | Low density lipoprotein | Cholesterol | Disease prevention | Blood pressure | Health risk assessment | Drug therapy | Heart diseases | Index Medicus | Abridged Index Medicus | Medical and Health Sciences | Medicin och hälsovetenskap
Journal Article
Clinical Pharmacology in Drug Development, ISSN 2160-763X, 11/2015, Volume 4, Issue 6, pp. 407 - 417
LCZ696 is a first-in-class angiotensin receptor neprilysin inhibitor in development for treatments of hypertension and heart failure indications. In 3 separate... 
LCZ696 | pharmacokinetic drug–drug interaction | amlodipine | hydrochlorothiazide | carvedilol | Pharmacokinetic drug-drug interaction | Amlodipine | Hydrochlorothiazide | Carvedilol | STEADY-STATE PHARMACOKINETICS | ANTAGONIST | NATRIURETIC PEPTIDES | pharmacokinetic drug-drug interaction | HEART-FAILURE | EXCRETION | PHARMACOLOGY & PHARMACY | DYSFUNCTION | VALSARTAN | Hydrochlorothiazide - pharmacokinetics | Diuretics - pharmacokinetics | Humans | Middle Aged | Male | Metabolic Clearance Rate | Tetrazoles - blood | Adrenergic beta-Antagonists - pharmacokinetics | Drug Interactions | Tetrazoles - administration & dosage | Adrenergic beta-Antagonists - adverse effects | Amlodipine - administration & dosage | Arizona | Diuretics - blood | Hydrochlorothiazide - adverse effects | Diuretics - administration & dosage | Administration, Oral | Amlodipine - adverse effects | Propanolamines - adverse effects | Antihypertensive Agents - adverse effects | Antihypertensive Agents - blood | Cross-Over Studies | Models, Biological | Calcium Channel Blockers - administration & dosage | Protease Inhibitors - blood | Calcium Channel Blockers - blood | Propanolamines - administration & dosage | Diuretics - adverse effects | Tetrazoles - pharmacokinetics | Angiotensin Receptor Antagonists - adverse effects | Angiotensin Receptor Antagonists - pharmacokinetics | Calcium Channel Blockers - adverse effects | Area Under Curve | Protease Inhibitors - pharmacokinetics | Carbazoles - administration & dosage | Aminobutyrates - adverse effects | Antihypertensive Agents - administration & dosage | Healthy Volunteers | Propanolamines - pharmacokinetics | Amlodipine - pharmacokinetics | Aminobutyrates - pharmacokinetics | Protease Inhibitors - administration & dosage | Protease Inhibitors - adverse effects | Adult | Female | Carbazoles - blood | Aminobutyrates - administration & dosage | Drug Therapy, Combination | Propanolamines - blood | Hydrochlorothiazide - blood | Adrenergic beta-Antagonists - administration & dosage | Adrenergic beta-Antagonists - blood | Carbazoles - adverse effects | Amlodipine - blood | Drug Administration Schedule | Hydrochlorothiazide - administration & dosage | Antihypertensive Agents - pharmacokinetics | Neprilysin - metabolism | Aminobutyrates - blood | Angiotensin Receptor Antagonists - blood | Carbazoles - pharmacokinetics | Neprilysin - antagonists & inhibitors | Tetrazoles - adverse effects | Calcium Channel Blockers - pharmacokinetics | Angiotensin Receptor Antagonists - administration & dosage | Prescription drugs | Beta blockers | Index Medicus
Journal Article
JAMA, ISSN 0098-7484, 09/2013, Volume 310, Issue 9, pp. 918 - 929
Journal Article
European Journal of Preventive Cardiology, ISSN 2047-4873, 12/2015, Volume 22, Issue 12, pp. 1609 - 1617
Journal Article
Journal of Hypertension, ISSN 0263-6352, 05/2003, Volume 21, Issue 5, pp. 875 - 886
BACKGROUNDThe prognostic benefits of blood pressure lowering treatment in elderly hypertensive patients were established more than a decade ago, but are less... 
Hypertension | Cardiovascular events | Angiotensin II type 1-receptor blockade | Cognitive function | Candesartan | Elderly | Prognosis | Prospective Studies | Follow-Up Studies | Humans | Antihypertensive Agents - administration & dosage | Dementia - diagnosis | Dementia - physiopathology | Hypertension - drug therapy | Male | Dose-Response Relationship, Drug | Benzimidazoles - administration & dosage | Time Factors | Tetrazoles - administration & dosage | Aged, 80 and over | Cardiovascular Diseases - mortality | Female | Blood Pressure - drug effects | Hypertension - mortality | Benzimidazoles - adverse effects | Hypertension - diagnosis | Benzimidazoles - therapeutic use | Cardiovascular Diseases - diagnosis | Hydrochlorothiazide - adverse effects | Severity of Illness Index | Cardiovascular Diseases - physiopathology | Double-Blind Method | Risk Reduction Behavior | Europe - epidemiology | Treatment Outcome | Hydrochlorothiazide - administration & dosage | Biomarkers - blood | Antihypertensive Agents - therapeutic use | Cognition - drug effects | Antihypertensive Agents - adverse effects | Survival Analysis | Helsinki Declaration | Tetrazoles - therapeutic use | Aged | Tetrazoles - adverse effects | Hydrochlorothiazide - therapeutic use | Index Medicus | Comparative Study | Cardiovascular Diseases/diagnosis/mortality/physiopathology | Dose-Response Relationship; Drug | Biological Markers/blood | Europe/epidemiology | Aged; 80 and over | Research Support; Non-U.S. Gov't | Antihypertensive Agents/administration & dosage/adverse effects/therapeutic use | Benzimidazoles/administration & dosage/adverse effects/therapeutic use | Hydrochlorothiazide/administration & dosage/adverse effects/therapeutic use | Tetrazoles/administration & dosage/adverse effects/therapeutic use | Dementia/diagnosis/physiopathology | Blood Pressure/drug effects | Cognition/drug effects | Hypertension/diagnosis/drug therapy/mortality
Journal Article
Lancet, The, ISSN 0140-6736, 2010, Volume 375, Issue 9721, pp. 1173 - 1181
Summary Background The Avoiding Cardiovascular Events through Combination Therapy in Patients Living with Systolic Hypertension (ACCOMPLISH) trial showed that... 
Internal Medicine | KIDNEY-DISEASE | AMLODIPINE | BENAZEPRIL | MEDICINE, GENERAL & INTERNAL | CONVERTING-ENZYME-INHIBITOR | ALBUMINURIA | NITRIC-OXIDE | INSUFFICIENCY | DIABETIC-NEPHROPATHY | BLOOD-PRESSURE | PROGRESSION | Blood Pressure | Calcium Channel Blockers - adverse effects | Benzazepines - adverse effects | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Antihypertensive Agents - administration & dosage | Hypertension - drug therapy | Kidney Failure, Chronic - urine | Male | Albuminuria | Angiotensin-Converting Enzyme Inhibitors - adverse effects | Cardiovascular Diseases - mortality | Female | Amlodipine - administration & dosage | Hydrochlorothiazide - adverse effects | Kidney Failure, Chronic - physiopathology | Diuretics - administration & dosage | Glomerular Filtration Rate | Double-Blind Method | Risk Factors | Amlodipine - adverse effects | Hydrochlorothiazide - administration & dosage | Angiotensin-Converting Enzyme Inhibitors - administration & dosage | Disease Progression | Hypertension - physiopathology | Antihypertensive Agents - adverse effects | Calcium Channel Blockers - administration & dosage | Kidney Failure, Chronic - complications | Creatinine - blood | Hypertension - complications | Aged | Benzazepines - administration & dosage | Diuretics - adverse effects | Drug Combinations | Hypertension | Chronic kidney failure | Patient outcomes | Development and progression | Drug therapy, Combination | Drug therapy | Methods | Risk factors | Studies | Heart failure | Blister packs | Mortality | Kidney diseases | Diabetes | Index Medicus | Abridged Index Medicus | Drugs | blood pressure | Side effects | Filtration | secondary analysis | Dialysis | clinical trials | hypertension | Kidney
Journal Article
INTERNATIONAL JOURNAL OF PHARMACEUTICS, ISSN 0378-5173, 04/2017, Volume 521, Issue 1-2, pp. 73 - 83
An innovative pediatric oral formulation of hydrochlorothiazide (HCT) (2 mg/mL), endowed with improved bioavailability and sustained release properties and... 
VITRO | Pediatrics | Oral bioavailability | DIURETIC ACTIVITY | NLC | STABILITY | COMPLEXES | CONTROLLED DRUG-DELIVERY | Hydrochlorothiazide | CARRIERS | Cyclodextrin | SLN | PHYSICOCHEMICAL CHARACTERIZATION | BETA-CYCLODEXTRIN | Sustained release | PHARMACOLOGY & PHARMACY | Solid lipid nanoparticles | Hydrochlorothiazide - pharmacokinetics | Nanoparticles - chemistry | Antihypertensive Agents - administration & dosage | Drug Carriers - administration & dosage | Biological Availability | Delayed-Action Preparations - chemistry | Hypertension - drug therapy | Lipids | Male | Drug Carriers - chemistry | Delayed-Action Preparations - administration & dosage | Nanoparticles - metabolism | Cyclodextrins - chemistry | Drug Compounding | Poloxamer - administration & dosage | Poloxamer - chemistry | Drug Evaluation, Preclinical - methods | Administration, Oral | Poloxamer - pharmacokinetics | Cyclodextrins - pharmacokinetics | Hydrochlorothiazide - chemistry | Rats | Hydrochlorothiazide - administration & dosage | Antihypertensive Agents - pharmacokinetics | Rats, Sprague-Dawley | Hypertension - metabolism | Antihypertensive Agents - chemistry | Animals | Cyclodextrins - administration & dosage | Pediatrics - methods | Nanoparticles - administration & dosage | Hypertension | Product enhancement | Analysis | Diuretics | Cyclodextrins | Dextrins | Nanoparticles | Surface active agents | Drug therapy, Combination | Children | Health aspects | Index Medicus
Journal Article